Alzheimer’s disease (AD) is the most common form of dementia. There is no treatment to stop disease progression or slow it down. Thus patient care continues to be based on…Continue readingAlzheimer’s Disease
Committed to patients, our passionate teams are investigating brain metabolism therapies, utilizing an innovative approach, with the goal of transforming the lives of people affected by serious neurodegenerative conditions.
MD1105 is being developed as a disease-modifying therapy in Alzheimer’s disease (undisclosed molecule and mechanism of action). While currently in the pre-clinical phase, MedDay anticipates entering the clinic in early…Continue readingMD1105
The story of MedDay began in 2011, when Frédéric Sedel, MD, PhD, a neurologist and neuroscientist met with Guillaume Brion, an entrepreneur with experience in drug development. Both used…Continue readingOur story
At MedDay, our guiding principle is focusing on the needs and outcomes of our patients, particularly those living with neurodegenerative diseases. Their welfare, and that of their families, is at…Continue readingFor Patients and Families
MD1003 is a highly-concentrated pharmaceutical-grade biotin (vitamin H). The dosage is 300 mg/day corresponding to 10,000 times the recommended daily intake of biotin. As such, MD1003 is no longer a…Continue readingOur Discovery Development Story